An experimental radiation drug called RYZ101 slowed the growth of advanced neuroendocrine tumors in patients whose earlier lutetium-based radiation therapy had stopped working, Bristol Myers Squibb said on October 12. The company said the phase 3 ACTION-1 trial met its main goal at a planned interim analysis of the ACTION-1 trial.
These are topline, company-reported results. Bristol Myers Squibb has not released the size of the benefit, and survival data are still being collected.
